Save

MagDI Australia Study

RECRUITING

The objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion (e. g. , one example of a small bowel clinical procedure requiring a side-to-side anastomosis).

Simpliy with AI

Study details:

The partial diversion of intestinal contents from the duodenum to the ileum via side-to-side duodeno-ileostomy is intended to facilitate weight management / loss in obese adults and improve metabolic outcomes in obese adults with and without type 2 diabetes mellitus (T2DM). Side-to-side anastomoses are currently created by sutures, staples, and anastomotic compression devices. The most common side-to-side anastomosis technique used today is stapling, requiring cutting of the intestines and staples remain behind in the body.

Linear staplers are available in different sizes (e. g. , 30mm, 45mm, 50mm, 60mm).

A predicate for this side-to-side duodeno-ileostomy diversion procedure is the single-anastomosis duodeno-ileostomy (SADI) procedure.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Between 18-65 years of age, at the time of informed consent.

Body Mass Index (BMI) between 30-50 kg/m2

Meets one of the following criteria: 1. Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) following previous sleeve gastrectomy (≥ 12 months); OR 2. Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) without previous sleeve gastrectomy and without plan to perform a concurrent sleeve gastrectomy. 3. Weight regain following previous sleeve gastrectomy (≥ 12 months).

Participant agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study.

Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.

Participant is indicated for, and has agreed to, a bariatric procedure involving a duodenal ileal anastomosis. The participant has also undergone the site standard of care evaluation for this type of procedure, which is expected to involve clinical assessments over a period of time by a multidisciplinary team and may include, but is not limited to, the following: screening for surgical safety, interviews to determine if the participant understands the procedure and post-operative demands, and whether the participant has the necessary social supports in place to help manage outcomes.

Exclusion criteria

Type 1 diabetes.

Use of injectable insulin.

Uncontrolled Type 2 Diabetes Mellitus (T2DM).

Investigator plans to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure.

Uncontrolled hypertension, dyslipidemia or sleep apnea.

Prior intestinal, colonic or duodenal surgery (other than bariatric).

Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the procedure, including scarring and abnormal anatomy.

Refractory gastro-esophageal reflux disease (GERD).

Barrett's disease.

Helicobacter pylori positive and/or active ulcer disease.

Large hiatal hernia.

Inflammatory bowel or colonic diverticulitis disease.

Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques.

Any anomaly preventing / contraindicating endoscopic or laparoscopic access and procedures.

Implantable pacemaker or defibrillator.

Psychiatric disorder, except well-controlled depression with medication for > 6 months.

History of substance abuse.

Pregnant, lactating, or planning pregnancy during the clinical investigation. Note: Female participants of childbearing age must agree to use safe contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release).

Any comorbidity or current status of participant's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the participant medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.

Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment site.

Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months post-procedure.

Any surgical or interventional procedure (including planned and/or scheduled) within the period of 30 days prior to and 30 days following the study procedure.

Any stroke/TIA ≤ 6 months prior to consent.

Requires chronic anticoagulation therapy (except aspirin).

Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.

Recent tobacco or nicotine product cessation ≤ 3 months prior to informed consent.

Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.

Participants with comorbidities that are likely to result in a life expectancy of ≤ 12 months.

Currently participating in an investigational drug or another device study that has not reached its primary endpoint: Note: Studies requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.

A positive COVID-19 test prior to the study procedure in accordance with local COVID-19 protocol.

Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-08-13

Primary completion: 2026-03-01

Study completion finish: 2026-05-30

Study type

TREATMENT

Phase

Trial ID

NCT06473831

Intervention or treatment

DEVICE: Magnet System, DI Biofragmentable

Conditions

• Type 2 Diabetes
• Obesity

Condition: Type 2 Diabetes, Obesity
DEVICE: Magnet System, DI Biofragmentable
Sydney, New South Wales, Australia and more
Sponsor: GT Metabolic Solutions, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Dr. Mark Magdy (affiliated with St. George Private Hospital)

Research sites nearby

Select from list below to view details:

Dr. Mark Magdy (affiliated with St. George Private Hospital)
Sydney, New South Wales, Australia
Upper GI Surgery
Sydney, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Magnet System, DI Biofragmentable GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)	DEVICE: Magnet System, DI Biofragmentable Anastomoses achieved by magnetic compression.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Feasibility and performance of the side-to-side anastomosis for duodeno-ileal diversion using the MagDI System.	The duodeno-ileal diversion will be considered feasible if it results in successful: * Placement of the Magnet System (≥ 90% alignment of magnets); and * Creation of a patent anastomosis confirmed radiologically, and * Passage of magnets without any surgical re-interventions. The primary endpoint will be met if the feasibility/performance is confirmed in ≥ 80% of enrolled and treated subjects.	From date of study index procedure through 90 days
Safety of the MagDI System	Freedom from serious adverse events related to the study device or study device procedure requiring additional emergency surgery or re-intervention, including: * All-cause mortality * Intestinal perforation and/or peritonitis * Intestinal obstruction * Life-threatening bleeding * Incidence of device malfunctions	Procedure, Day 90, Day 180, Day 360

Secondary outcome

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: MagDI Australia Study